# Do Metastatic Cells Arise from PD-L1+ Cell Niches in Gastric Adenocarcinoma?

**Authors:** Erika P. Rendón-Huerta, Ricardo Meléndez-Rendón, At-Sat Aguilar, Luis F. Montano

PMC · DOI: 10.3390/ijms27041829 · International Journal of Molecular Sciences · 2026-02-14

## TL;DR

This review explores how PD-L1+ cell niches in gastric cancer may contribute to metastasis and immune evasion.

## Contribution

The paper proposes a novel hypothesis that PD-L1+ cancer stem cells form niches that drive metastasis in gastric adenocarcinoma.

## Key findings

- Metastasis in gastric cancer involves epithelial-mesenchymal transition and immune evasion.
- PD-L1+ cancer stem cells may form niches that serve as sources of metastatic cells.
- Understanding these niches could lead to new therapeutic strategies for gastric cancer.

## Abstract

Gastric cancer (GC), one of the most common malignancies worldwide, is strongly linked to metastasis, significantly worsening prognosis and survival rates. Metastasis initiation relies on epithelial cells undergoing an epithelial–mesenchymal transition and on an abnormal, leaky vasculature. Although the tumor cells involved in the metastatic process have a progression-associated gene signature associated with extracellular matrix organization and the epithelial-to-mesenchymal transition, they must originate from an immune-evasive ecosystem that allows tumors to hinder or evade immune surveillance, either by secreting immunosuppressive chemicals, recruiting regulatory immune cells, or expressing negative stimulatory immune checkpoint molecules such as PD-L1. Although the mechanism underlying the so-called “metastatic cascade” is beginning to emerge, the tumor microenvironment, or niche, in which metastatic cells arise, remains unknown. In this review, we speculate that the epithelial–mesenchymal transition generates PD-L1-expressing cancer stem cells within the primary tumor, which can form tumor niches that serve as sources of metastatic cells within the gastric adenocarcinoma microenvironment. Understanding the regulatory pathways governing metastasis may offer new avenues for developing more effective therapeutic approaches.

## Linked entities

- **Proteins:** CD274 (CD274 molecule)
- **Diseases:** gastric cancer (MONDO:0001056), gastric adenocarcinoma (MONDO:0005036)

## Full-text entities

- **Genes:** ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, CLDN9 (claudin 9) [NCBI Gene 9080] {aka DFNB116}, IRF1 (interferon regulatory factor 1) [NCBI Gene 3659] {aka IMD117, IRF-1, MAR}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 396750] {aka ICAM-1}, ITIH3 (inter-alpha-trypsin inhibitor heavy chain 3) [NCBI Gene 3699] {aka H3P, ITI-HC3, SHAP}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CMTM3 (CKLF like MARVEL transmembrane domain containing 3) [NCBI Gene 123920] {aka BNAS2, CKLFSF3}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, VIM (vimentin) [NCBI Gene 7431], MIR570 (microRNA 570) [NCBI Gene 693155] {aka MIRN570, hsa-mir-570}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}, ICOS (inducible T cell costimulator) [NCBI Gene 29851] {aka AILIM, CD278, CVID1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, MIR424 (microRNA 424) [NCBI Gene 494336] {aka MIR322, MIRN424, hsa-mir-424, miRNA424, mir-424}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, CD44 [NCBI Gene 100126860], EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}, CMTM6 (CKLF like MARVEL transmembrane domain containing 6) [NCBI Gene 54918] {aka CKLFSF6, PRO2219}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, MIR17 (microRNA 17) [NCBI Gene 406952] {aka MIR17-5p, MIR91, MIRN17, MIRN91, hsa-mir-17, miR-17}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, WWC1 (WW and C2 domain containing 1) [NCBI Gene 23286] {aka HBEBP3, HBEBP36, KIBRA, MEMRYQTL, PPP1R168}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CD24 (CD24 molecule) [NCBI Gene 100133941] {aka CD24A}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, STAT2 (signal transducer and activator of transcription 2) [NCBI Gene 6773] {aka IMD44, ISGF-3, P113, PTORCH3, STAT113}, STT3A (STT3 oligosaccharyltransferase complex catalytic subunit A) [NCBI Gene 3703] {aka CDG1WAD, CDG1WAR, ITM1, STT3-A, TMC}, SIGLEC1 (sialic acid binding Ig like lectin 1) [NCBI Gene 6614] {aka CD169, SIGLEC-1, SN}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, PDCD1LG2 (programmed cell death 1 ligand 2) [NCBI Gene 80380] {aka B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2}, YY1 (YY1 transcription factor) [NCBI Gene 7528] {aka DELTA, GADEVS, INO80S, NF-E1, UCRBP, YIN-YANG-1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TWIST1 (twist family bHLH transcription factor 1) [NCBI Gene 7291] {aka ACS3, BPES2, BPES3, CRS, CRS1, CSO}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, YY1AP1 (YY1 associated protein 1) [NCBI Gene 55249] {aka GRNG, HCCA1, HCCA2, YY1AP}, ST3GAL4 (ST3 beta-galactoside alpha-2,3-sialyltransferase 4) [NCBI Gene 6484] {aka CGS23, NANTA3, SAT3, SIAT4, SIAT4C, ST-4}
- **Diseases:** Tumorigenesis (MESH:D063646), hypoxic (MESH:D002534), GC (MESH:D013274), hypoxia (MESH:D000860), pancreatic duct adenocarcinoma (MESH:D010190), inflammation (MESH:D007249), injury to (MESH:D014947), melanoma (MESH:D008545), fibrosis (MESH:D005355), metastatic (MESH:D000092182), colon and lung cancer (MESH:D008175), Metastatic Cancer (MESH:D009369), gastric (MESH:D013272), breast cancer (MESH:D001943), precancerous (MESH:D011230), tumorigenicity (MESH:D002471), Metastases (MESH:D009362), tumor suppressor protein (OMIM:601308), peritoneal metastasis (MESH:D010538)
- **Chemicals:** sialic acid (MESH:D019158), lactate (MESH:D019344), nivolumab (MESH:D000077594), BioRender (-), pembrolizumab (MESH:C582435)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** AGS — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0139)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940350/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940350/full.md

## References

155 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940350/full.md

---
Source: https://tomesphere.com/paper/PMC12940350